The Use of Biologic Therapies in Uveitis (Q38272248)

1 September 2017

1 reference

title

The Use of Biologic Therapies in Uveitis (English)

1 reference

1 September 2017

1 reference

Sergio Schwartzman

1

1 reference

1 September 2017

Monica Schwartzman

series ordinal

2

1 reference

1 September 2017

publication date

29 November 2014

1 reference

Clinical Reviews in Allergy & Immunology

1 September 2017

published in

1 reference

1 September 2017

volume

49

1 reference

1 September 2017

issue

3

1 reference

1 September 2017

page(s)

307-316

1 reference

Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Mycophenolate sodium for immunosuppressive treatment in uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Mycophenolate mofetil use in the treatment of noninfectious uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Immunosuppressive therapy for chronic uveitis: optimising therapy with steroids and cyclosporin A

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Retrospective case review of pediatric patients with uveitis treated with infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Infliximab for juvenile idiopathic arthritis-associated uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: efficacy in joint and ocular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Prevention of flare recurrences in childhood‐refractory chronic uveitis: An open‐label comparative study of adalimumab versus infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Infliximab-induced Demyelination Causes Visual Disturbance Mistaken for Recurrence of HLA-B27-related Uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Use of adalimumab in refractory non-infectious childhood chronic uveitis: efficacy in ocular disease--a case cohort interventional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Adalimumab for sight-threatening uveitis in Behçet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Infliximab and adalimumab for uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Adalimumab in the therapy of uveitis in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Adalimumab for juvenile idiopathic arthritis-associated uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Optic Neuritis Associated with Adalimumab in the Treatment of Uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

A three-centre experience with adalimumab for the treatment of non-infectious uveitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Serum cytokine profile in adalimumab-treated refractory uveitis patients: decreased IL-22 correlates with clinical responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Adalimumab specifically induces CD3( ) CD4( ) CD25(high) Foxp3( ) CD127(-) T-regulatory cells and decreases vascular endothelial growth factor plasma levels in refractory immuno-mediated uveitis: a non-randomized pilot intervention study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Adalimumab therapy for refractory childhood uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Adalimumab in the therapy of uveitis in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Intravitreal adalimumab for refractory uveitis-related macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Etanercept therapy in children with treatment-resistant uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Efficacy of Etanercept in Preventing Relapse of Uveitis Controlled by Methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

GRADE guidelines: 3. Rating the quality of evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Cytokines and chemokines in uveitis: is there a correlation with clinical phenotype?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Tocilizumab treatment for refractory uveitis-related cystoid macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Rituximab for noninfectious uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Immunohistochemical study of chronic nongranulomatous anterior uveitis in juvenile idiopathic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

Behçet Disease-associated Uveitis Successfully Treated with Golimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-014-8455-6

IL-23 promotes CD4 T cells to produce IL-17 in Vogt-Koyanagi-Harada disease

21 January 2018

1 reference

12 December 2020

Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study

1 reference

12 December 2020

Adalimumab therapy for refractory uveitis: a pilot study

1 reference

12 December 2020

Treatment of recurrent anterior uveitis with infliximab in patient with ankylosing spondylitis

1 reference

12 December 2020

Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders

1 reference

12 December 2020

Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials

1 reference

12 December 2020

Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis

1 reference

12 December 2020

Treatment of acute uveitis associated with Crohn's disease and sacroileitis with infliximab

1 reference

12 December 2020

Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease-related uveitis

1 reference

12 December 2020

Infliximab therapy for refractory uveitis: 2-year results of a prospective trial

1 reference

12 December 2020

Adalimumab therapy for refractory uveitis: a pilot study

1 reference

12 December 2020

Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis?

1 reference

12 December 2020

Use of methotrexate in patients with uveitis

1 reference

12 December 2020

Treatment of recurrent Crohn's uveitis with infliximab

1 reference

12 December 2020

Low-dose cyclosporin A therapy in treating chronic, noninfectious uveitis

1 reference

12 December 2020

Adalimumab therapy for childhood uveitis

1 reference

12 December 2020

Favorable response to high-dose infliximab for refractory childhood uveitis

1 reference

12 December 2020

Tocilizumab for severe chronic anterior uveitis associated with juvenile idiopathic arthritis in a pediatric patient.

1 reference

12 December 2020

Treatment of seronegative spondyloarthropathy-associated uveitis with golimumab: retrospective case series

1 reference

12 December 2020

Long-term effects of intravitreal infliximab for treatment of sight-threatening chronic noninfectious uveitis

1 reference

12 December 2020

Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab)

1 reference

12 December 2020

A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis

1 reference

12 December 2020

Infliximab for the treatment of refractory noninfectious Uveitis: a study of 88 patients with long-term follow-up

1 reference

12 December 2020

Do tumor necrosis factor inhibitors cause uveitis? A registry-based study

1 reference

12 December 2020

Psoriatic uveitis responding to adalimumab therapy

1 reference

12 December 2020

Efficacy of switching to adalimumab in a patient with refractory uveitis of Behçet's disease to infliximab

1 reference

12 December 2020

1 reference

12 December 2020

Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series

1 reference

12 December 2020

Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: two new cases. Comment on the article by Zulian et al

1 reference

12 December 2020

Intravitreal infliximab for sight-threatening relapsing uveitis in Behçet disease: a pilot study in 15 patients

1 reference

12 December 2020

Long-term follow-up of tacrolimus treatment in immune posterior uveitis

1 reference

12 December 2020

Rituximab for uveitis

1 reference

12 December 2020

Rituximab as a treatment option for refractory endogenous anterior uveitis

1 reference

12 December 2020

Long-term treatment with golimumab for severe uveitis

1 reference

12 December 2020

Interleukin 6 and its soluble receptor are elevated in aqueous humor of patients with uveitis

1 reference

12 December 2020

Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis

1 reference

12 December 2020

Golimumab for uveitis

1 reference

12 December 2020

Comparison of acute effect of systemic versus intravitreal infliximab treatment in an experimental model of endotoxin-induced uveitis

1 reference

12 December 2020

Etanercept and uveitis in patients with juvenile idiopathic arthritis.

1 reference

12 December 2020

Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis

1 reference

12 December 2020

Abatacept for refractory juvenile idiopathic arthritis-associated uveitis- a case report

1 reference

12 December 2020

Therapeutic experience with infliximab in a patient with polyarticular juvenile idiopathic arthritis and uveitis

1 reference

12 December 2020

Intravitreal infliximab in experimental endotoxin-induced uveitis

1 reference

12 December 2020

Golimumab treatment for complicated uveitis

1 reference

12 December 2020

Corticosteroid-sparing effect of etanercept in idiopathic panuveitis resistant to immunosuppressive therapy.

1 reference

12 December 2020

Bilateral uveitis after phakic intraocular lens implantation and management with adalimumab

1 reference

12 December 2020

Anakinra for resistant Behçet uveitis: why not?

1 reference

12 December 2020

10.1007/S12016-014-8455-6

Identifiers

DOI

1 reference

Dimensions Publication ID

1 September 2017

1018977357

0 references

1 reference